Bio-Path (BPTH) Competitors $0.16 0.00 (-1.90%) As of 07/24/2025 03:54 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. ENSC, QLGN, SPRB, VIVS, MTNB, ORGS, GLTO, ADIL, GRI, and REVBShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Ensysce Biosciences (ENSC), Qualigen Therapeutics (QLGN), Spruce Biosciences (SPRB), VivoSim Labs (VIVS), Matinas Biopharma (MTNB), Orgenesis (ORGS), Galecto (GLTO), Adial Pharmaceuticals (ADIL), GRI Bio (GRI), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Its Competitors Ensysce Biosciences Qualigen Therapeutics Spruce Biosciences VivoSim Labs Matinas Biopharma Orgenesis Galecto Adial Pharmaceuticals GRI Bio Revelation Biosciences Bio-Path (NASDAQ:BPTH) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations. Which has more risk & volatility, BPTH or ENSC? Bio-Path has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Which has stronger valuation & earnings, BPTH or ENSC? Ensysce Biosciences has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/AEnsysce Biosciences$5.21M1.00-$7.99M-$6.54-0.34 Is BPTH or ENSC more profitable? Bio-Path has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -109.49%. Ensysce Biosciences' return on equity of -192.54% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% Ensysce Biosciences -109.49%-192.54%-121.77% Does the media refer more to BPTH or ENSC? In the previous week, Ensysce Biosciences had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for Ensysce Biosciences and 0 mentions for Bio-Path. Ensysce Biosciences' average media sentiment score of 1.89 beat Bio-Path's score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Bio-Path Neutral Ensysce Biosciences Very Positive Do institutionals & insiders have more ownership in BPTH or ENSC? 5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryEnsysce Biosciences beats Bio-Path on 8 of the 10 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.31M$815.90M$5.72B$9.47BDividend YieldN/A4.84%4.60%3.99%P/E RatioN/A1.3827.9419.95Price / SalesN/A26.59452.94100.82Price / CashN/A19.5636.5558.97Price / Book0.226.818.645.90Net Income-$16.08M-$4.28M$3.24B$258.42M7 Day Performance-0.64%1.60%3.69%2.11%1 Month Performance-11.43%4.40%10.33%12.44%1 Year Performance-91.14%9.12%34.30%19.55% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path0.9665 of 5 stars$0.16-1.9%N/A-91.0%$1.31MN/A0.0010ENSCEnsysce Biosciences1.0237 of 5 stars$2.17+1.9%N/A-63.2%$5.05M$5.21M-0.3310QLGNQualigen TherapeuticsN/A$3.07+2.0%N/A-74.5%$4.92M$4.98M0.0050Earnings ReportGap DownSPRBSpruce Biosciences2.2041 of 5 stars$0.12+5.7%$1.75+1,404.7%-77.5%$4.91M$4.91M-0.1220News CoverageStock SplitGap DownVIVSVivoSim LabsN/A$1.98+4.8%N/AN/A$4.91M$140K-0.1920MTNBMatinas BiopharmaN/A$0.95-0.6%N/AN/A$4.85MN/A-0.2030Gap DownORGSOrgenesis1.8698 of 5 stars$1.01-2.9%N/AN/A$4.85M$662K0.00150Gap UpGLTOGalecto3.7617 of 5 stars$3.60+0.3%$10.00+177.8%-72.3%$4.74MN/A-0.2340ADILAdial Pharmaceuticals2.9655 of 5 stars$0.51+12.4%$8.00+1,477.9%-59.6%$4.71MN/A-0.3520GRIGRI Bio2.4351 of 5 stars$1.99+9.3%$22.00+1,005.5%-91.4%$4.54MN/A-0.171Positive NewsGap UpREVBRevelation Biosciences1.7629 of 5 stars$3.06+3.7%N/A-96.2%$4.53MN/A-0.0110High Trading Volume Related Companies and Tools Related Companies ENSC Alternatives QLGN Alternatives SPRB Alternatives VIVS Alternatives MTNB Alternatives ORGS Alternatives GLTO Alternatives ADIL Alternatives GRI Alternatives REVB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
